Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Non-Current Liabilities: 2010-2025

Historic Other Non-Current Liabilities for Lineage Cell Therapeutics (LCTX) over the last 12 years, with Sep 2025 value amounting to $45.2 million.

  • Lineage Cell Therapeutics' Other Non-Current Liabilities was N/A to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year change of. This contributed to the annual value of $6.2 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Other Non-Current Liabilities of $45.2 million as of Q3 2025, which was up 140.26% from $18.8 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Other Non-Current Liabilities ranged from a high of $45.2 million in Q3 2025 and a low of $1,000 during Q1 2023.
  • Over the past 3 years, Lineage Cell Therapeutics' median Other Non-Current Liabilities value was $6.1 million (recorded in 2024), while the average stood at $12.7 million.
  • In the last 5 years, Lineage Cell Therapeutics' Other Non-Current Liabilities spiked by 69.23% in 2021 and then slumped by 98.80% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $30,000 in 2021, then plummeted by 93.33% to $2,000 in 2022, then slumped by 75.00% to $1,000 in 2023, then reached $6.2 million in 2024, then reached $45.2 million in 2025.
  • Its last three reported values are $45.2 million in Q3 2025, $18.8 million for Q2 2025, and $6.1 million during Q1 2025.